Skip to main content
CLNN
NASDAQ Life Sciences

Clene Inc. Director David J. Matlin Makes $903K Unit Purchase Including Common Stock and Warrants

Analysis by Wiseek.aiReviewed by Editorial Team
Sentiment info
Positive
Importance info
9
Price
$5.15
Mkt Cap
$60.069M
52W Low
$2.28
52W High
$13.5
Market data snapshot near publication time

summarizeSummary

A director of Clene Inc. acquired common stock and warrants totaling $903,329 in an open market transaction, signaling strong confidence in the company's future prospects.


check_boxKey Events

  • Director's Substantial Investment

    David J. Matlin, a director, acquired units consisting of common stock and warrants for a total of $903,329.

  • Open Market Purchase of Common Stock

    The transaction included an open market purchase of 33,333 shares of common stock at $6.50 per share, totaling $216,664.50.

  • Acquisition of Warrants

    As part of the unit purchase, the director also received Series A Warrants to purchase 40,000 shares and Series B Warrants to purchase 93,333 shares.

  • Premium Purchase Price

    The unit purchase price of $6.50 is above the current stock price of $5.15, indicating strong conviction from the director.


auto_awesomeAnalysis

This Form 4 filing signals a strong vote of confidence from Director David J. Matlin in Clene Inc. The total investment of $903,329, which includes both common stock and warrants, represents a substantial capital commitment for a micro-cap company. The unit purchase price of $6.50, which includes common stock, is notably higher than the current market price of $5.15, suggesting the director sees considerable upside potential. The acquisition of warrants further amplifies this bullish outlook, as warrants provide leverage to future stock price appreciation. This significant insider buying activity could be interpreted by investors as a strong positive signal, especially given the company's micro-cap status where such investments can have a more pronounced impact on sentiment.

At the time of this filing, CLNN was trading at $5.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $60.1M. The 52-week trading range was $2.28 to $13.50. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed CLNN - Latest Insights

CLNN
Apr 22, 2026, 5:55 PM EDT
Filing Type: 4
Importance Score:
7
CLNN
Apr 17, 2026, 8:17 PM EDT
Filing Type: 4
Importance Score:
7
CLNN
Apr 15, 2026, 4:05 PM EDT
Filing Type: 144
Importance Score:
8
CLNN
Apr 10, 2026, 4:06 PM EDT
Filing Type: DEFA14A
Importance Score:
8
CLNN
Apr 10, 2026, 4:05 PM EDT
Filing Type: DEF 14A
Importance Score:
8
CLNN
Mar 31, 2026, 5:05 PM EDT
Filing Type: 144
Importance Score:
7
CLNN
Mar 31, 2026, 4:35 PM EDT
Filing Type: 4
Importance Score:
7
CLNN
Mar 24, 2026, 4:36 PM EDT
Filing Type: 144
Importance Score:
8
CLNN
Mar 17, 2026, 7:00 AM EDT
Filing Type: 10-K
Importance Score:
9
CLNN
Mar 16, 2026, 6:15 PM EDT
Filing Type: 8-K
Importance Score:
8